{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:06:58Z","timestamp":1790705218057,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00228-020-03072-y","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T02:11:50Z","timestamp":1610676710000},"page":"989-998","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment"],"prefix":"10.1007","volume":"77","author":[{"given":"Wanhong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6043-9187","authenticated-orcid":false,"given":"Cuihong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"issue":"7","key":"3072_CR1","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s40262-017-0623-4","volume":"57","author":"V Al Jalali","year":"2018","unstructured":"Al Jalali V, Zeitlinger M (2018) Clinical pharmacokinetics and pharmacodynamics of telavancin compared with the other glycopeptides. Clin Pharmacokinet 57(7):797\u2013816. https:\/\/doi.org\/10.1007\/s40262-017-0623-4","journal-title":"Clin Pharmacokinet"},{"key":"3072_CR2","volume-title":"VIBATIV\u00ae (telavancin) for injection, for intravenous use [prescribing information]","author":"Cumberland Pharmaceuticals Inc","year":"2020","unstructured":"Cumberland Pharmaceuticals Inc (2020) VIBATIV\u00ae (telavancin) for injection, for intravenous use [prescribing information]. Cumberland Pharmaceuticals Inc., Nashville, TN 37203"},{"issue":"7","key":"3072_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/17425255.2016.1187599","volume":"12","author":"L Adamantia","year":"2016","unstructured":"Adamantia L, Antoni T (2016) Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia. Expert Opin Drug Metab Toxicol 12(7):803\u2013812. https:\/\/doi.org\/10.1080\/17425255.2016.1187599","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"3072_CR4","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1128\/aac.01750-09","volume":"54","author":"JP Shaw","year":"2010","unstructured":"Shaw JP, Cheong J, Goldberg MR, Kitt MM (2010) Mass balance and pharmacokinetics of [14C] telavancin following intravenous administration to healthy male volunteers. Antimicrob Agents Chemother 54(8):3365\u20133371. https:\/\/doi.org\/10.1128\/aac.01750-09","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"3072_CR5","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1128\/aac.50.3.862-867.2006","volume":"50","author":"M Stryjewski","year":"2006","unstructured":"Stryjewski M, Chu V, O'Riordan W, Warren B, Dunbar L, Young D, Vall\u00e9e M, Fowler V, Morganroth J, Barriere S, Kitt M, Corey G (2006) Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 50(3):862\u2013867. https:\/\/doi.org\/10.1128\/aac.50.3.862-867.2006","journal-title":"Antimicrob Agents Chemother"},{"key":"3072_CR6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3389\/fphar.2016.00330","volume":"7","author":"J Chuan","year":"2016","unstructured":"Chuan J, Zhang Y, He X, Zhu Y, Zhong L, Yu D, Xiao H (2016) Systematic review and meta-analysis of the efficacy and safety of telavancin for treatment of infectious disease: are we clearer? Front Pharmacol 7:330. https:\/\/doi.org\/10.3389\/fphar.2016.00330","journal-title":"Front Pharmacol"},{"issue":"5","key":"3072_CR7","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1128\/aac.05002-14","volume":"59","author":"V Tam","year":"2015","unstructured":"Tam V, Ledesma K, Bowers D, Zhou J, Truong L (2015) Kidney injury associated with telavancin dosing regimen in an animal model. Antimicrob Agents Chemother 59(5):2930\u20132933. https:\/\/doi.org\/10.1128\/aac.05002-14","journal-title":"Antimicrob Agents Chemother"},{"key":"3072_CR8","doi-asserted-by":"publisher","unstructured":"Bunnell K, Pai M, Sikka M, Bleasdale S, Wenzler E, Danziger L, Rodvold K (2018) Pharmacokinetics of telavancin at fixed doses in normal-body-weight and obese (classes I, II, and III) adult subjects. Antimicrob Agents Chemother 62(4). https:\/\/doi.org\/10.1128\/aac.02475-17","DOI":"10.1128\/aac.02475-17"},{"issue":"2","key":"3072_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/qco.0000000000000356","volume":"30","author":"M Grupper","year":"2017","unstructured":"Grupper M, Nicolau D (2017) Obesity and skin and soft tissue infections: how to optimize antimicrobial usage for prevention and treatment? Curr Opin Infect Dis 30(2):180\u2013191. https:\/\/doi.org\/10.1097\/qco.0000000000000356","journal-title":"Curr Opin Infect Dis"},{"issue":"11","key":"3072_CR10","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1002\/phar.2023","volume":"37","author":"L Meng","year":"2017","unstructured":"Meng L, Mui E, Holubar M, Deresinski S (2017) Comprehensive guidance for antibiotic dosing in obese adults. Pharmacotherapy 37(11):1415\u20131431. https:\/\/doi.org\/10.1002\/phar.2023","journal-title":"Pharmacotherapy"},{"key":"3072_CR11","doi-asserted-by":"publisher","unstructured":"Promsan S, Lungkaphin A (2020) The roles of melatonin on kidney injury in obese and diabetic conditions. BioFactors (Oxford, England). https:\/\/doi.org\/10.1002\/biof.1637","DOI":"10.1002\/biof.1637"},{"issue":"8","key":"3072_CR12","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s11255-020-02501-2","volume":"52","author":"R Kawamoto","year":"2020","unstructured":"Kawamoto R, Kikuchi A, Akase T, Ninomiya D, Kasai Y, Ohtsuka N, Kumagi T (2020) Increased body mass index above the upper normal limit is significantly associated with renal dysfunction among community-dwelling persons. Int Urol Nephrol 52(8):1533\u20131541. https:\/\/doi.org\/10.1007\/s11255-020-02501-2","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"3072_CR13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00228-015-1847-6","volume":"71","author":"P Worboys","year":"2015","unstructured":"Worboys P, Wong S, Barriere S (2015) Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. Eur J Clin Pharmacol 71(6):707\u2013714. https:\/\/doi.org\/10.1007\/s00228-015-1847-6","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"3072_CR14","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1016\/j.xphs.2017.04.035","volume":"106","author":"N Marsousi","year":"2017","unstructured":"Marsousi N, Desmeules J, Rudaz S, Daali Y (2017) Usefulness of PBPK modeling in incorporation of clinical conditions in personalized medicine. J Pharm Sci 106(9):2380\u20132391. https:\/\/doi.org\/10.1016\/j.xphs.2017.04.035","journal-title":"J Pharm Sci"},{"issue":"8","key":"3072_CR15","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1592\/phco.30.8.806","volume":"30","author":"M Goldberg","year":"2010","unstructured":"Goldberg M, Wong S, Shaw J, Kitt M, Barriere S (2010) Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. Pharmacotherapy 30(8):806\u2013811. https:\/\/doi.org\/10.1592\/phco.30.8.806","journal-title":"Pharmacotherapy"},{"issue":"2","key":"3072_CR16","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1128\/aac.50.2.788-790.2006","volume":"50","author":"H Sun","year":"2006","unstructured":"Sun H, Duchin K, Nightingale C, Shaw J, Seroogy J, Nicolau D (2006) Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother 50(2):788\u2013790. https:\/\/doi.org\/10.1128\/aac.50.2.788-790.2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3072_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1128\/aac.00875-07","volume":"52","author":"M Gotfried","year":"2008","unstructured":"Gotfried M, Shaw J, Benton B, Krause K, Goldberg M, Kitt M, Barriere S (2008) Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Antimicrob Agents Chemother 52(1):92\u201397. https:\/\/doi.org\/10.1128\/aac.00875-07","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"3072_CR18","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ijantimicag.2011.08.012","volume":"38","author":"M Rashid","year":"2011","unstructured":"Rashid M, Weintraub A, Nord C (2011) Effect of telavancin on human intestinal microflora. Int J Antimicrob Agents 38(6):474\u2013479. https:\/\/doi.org\/10.1016\/j.ijantimicag.2011.08.012","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"3072_CR19","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1128\/aac.05915-11","volume":"56","author":"E Samara","year":"2012","unstructured":"Samara E, Shaw J, Barriere S, Wong S, Worboys P (2012) Population pharmacokinetics of telavancin in healthy subjects and patients with infections. Antimicrob Agents Chemother 56(4):2067\u20132073. https:\/\/doi.org\/10.1128\/aac.05915-11","journal-title":"Antimicrob Agents Chemother"},{"key":"3072_CR20","doi-asserted-by":"publisher","unstructured":"Lepak A, Zhao M, Andes D (2017) Comparative pharmacodynamics of telavancin and vancomycin in the veutropenic murine thigh and lung infection models against staphylococcus aureus. Antimicrob Agents Chemother 61(7). https:\/\/doi.org\/10.1128\/aac.00281-17","DOI":"10.1128\/aac.00281-17"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03072-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-020-03072-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-020-03072-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:34:22Z","timestamp":1744151662000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-020-03072-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["3072"],"URL":"https:\/\/doi.org\/10.1007\/s00228-020-03072-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"2 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}